Nuvalent Inc

NUVL

Healthcare|Biotechnology|USA

$123.90

+0.06 (+0.05%)

Tangible Book

$14.89

About

Nuvalent Inc is a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of its operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically validated kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.

Stock Price

+51.0%(1Y)

Pipeline Summary

6 total trials

Phase 1

Phase 2

Phase 3

Phase 4

AVAILABLE: 2Recruiting: 4

Active Trials (4)

A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1)

NCT05118789Locally Advanced Solid Tumor

Phase 1Phase 2Recruiting

Enrollment: 359 participants

A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)

NCT05384626Locally Advanced Solid Tumor

Phase 1Phase 2Recruiting

Enrollment: 840 participants

A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1)

NCT06521554Locally Advanced Solid Tumor

Phase 1Recruiting

Enrollment: 200 participants

Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC

NCT06765109Non-small Cell Lung Cancer

Phase 3Recruiting

Enrollment: 450 participants

BioScore

4.8/10

Cautious

Ownership

Recent Insider Trades

Pelish Henry E.SELL

2026-07-092,111 shares @ $123.81

Porter James RichardSELL

2026-07-0630,000 shares @ $123.72

Noci DarleneSELL

2026-07-0123,000 shares @ $123.59

Balcom AlexandraSELL

2026-07-0111,430 shares @ $123.58

Noci DarleneSELL

2026-06-295,500 shares @ $123.51

Recent News

2026-07-09 08:56:56

2026-06-24 20:00:04

2026-06-24 12:32:02

2026-06-22 22:00:04

Data last updated: Jul 12, 2026, 07:36 PM